CIK 0001437402
- Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K Reporting owner sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-04 | Rosenbaum David P. Chief Development Officer | Sale | −27,172 | $5.95 | $162K | 153,616 |
| 2024-11-04 | Rosenbaum David P. Chief Development Officer | Exercise or conversion · Stock Option (Right to Buy) | −27,172 | $2.32 | $63K | 27,171 |
| 2024-10-28 | RAAB MICHAEL President & CEO | Exercise or conversion 10b5-1 | +25,000 | $0.99 | $25K | 1,235,108 |
| 2024-10-28 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −25,000 | $5.91 | $148K | 1,210,108 |
| 2024-10-28 | RAAB MICHAEL President & CEO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −25,000 | 545,000 | ||
| 2024-10-11 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −7,500 | $6.01 | $45K | 1,210,108 |
| 2024-09-27 | Rosenbaum David P. Chief Development Officer | Sale 10b5-1 | −49,564 | $6.92 | $343K | 301,946 |
| 2024-09-26 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −3,000 | $6.07 | $18K | 1,217,608 |
| 2024-09-13 | Rosenbaum David P. Chief Development Officer | Sale | −5,312 | $6.26 | $33K | 153,616 |
| 2024-09-11 | RAAB MICHAEL President & CEO | Exercise or conversion | +35,000 | $0.99 | $35K | 1,255,608 |
| 2024-09-11 | RAAB MICHAEL President & CEO | Sale | −35,000 | $5.61 | $196K | 1,220,608 |
| 2024-09-11 | RAAB MICHAEL President & CEO | Exercise or conversion · Stock Option (Right to Buy) | −35,000 | 570,000 | ||
| 2024-08-27 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −7,500 | $6.22 | $47K | 1,219,509 |
| 2024-08-20 | Williams Laura A Chief Medical Officer | Sale | −7,412 | $5.86 | $43K | 314,740 |
| 2024-08-20 | Rosenbaum David P. Chief Development Officer | Sale | −4,969 | $5.86 | $29K | 351,510 |
| 2024-08-20 | Rosenbaum David P. Chief Development Officer | Sale | −2,250 | $5.86 | $13K | 156,252 |
| 2024-08-20 | Renz Justin A Chief Financial Officer | Sale | −5,289 | $5.86 | $31K | 295,257 |
| 2024-08-20 | RAAB MICHAEL President & CEO | Sale | −32,225 | $5.86 | $189K | 1,227,009 |
| 2024-08-20 | GRAMMER ELIZABETH A | Sale | −7,089 | $5.86 | $42K | 192,380 |
| 2024-08-20 | Felsch Robert Ora | Sale | −3,567 | $5.86 | $21K | 91,560 |
Page 12 of 18 · 360 trades